For instance, in relapsed/refractory B-cell malignancies, including NHL and ALL, CD19 was a marker of choice for most CAR-NK designs, while in multiple myeloma, BCMA (B cell maturation antigen) was the preferred target (Supplementary Table S1). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.